|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0023981,
umls-concept:C0034656,
umls-concept:C0079747,
umls-concept:C0205217,
umls-concept:C0205269,
umls-concept:C0334634,
umls-concept:C0393022,
umls-concept:C0439682,
umls-concept:C0871261,
umls-concept:C1257890,
umls-concept:C1274040,
umls-concept:C1521828,
umls-concept:C1556085,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2603343,
umls-concept:C2911692
|
|
pubmed:issue |
43
|
|
pubmed:dateCreated |
2002-10-24
|
|
pubmed:abstractText |
Rituximab has shown a high activity in relapsed follicular lymphomas when given alone. Further on, phase-II-studies indicate that its addition to chemotherapy may improve the response rate substantially. However, so far, prospective randomized studies have not been available.
|
|
pubmed:language |
ger
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal...,
http://linkedlifedata.com/resource/pubmed/chemical/Antimetabolites,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Mitoxantrone,
http://linkedlifedata.com/resource/pubmed/chemical/Vidarabine,
http://linkedlifedata.com/resource/pubmed/chemical/fludarabine,
http://linkedlifedata.com/resource/pubmed/chemical/rituximab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0012-0472
|
|
pubmed:author |
pubmed-author:BöckH PHP,
pubmed-author:ForstpointnerRR,
pubmed-author:HänelAA,
pubmed-author:HartmannFF,
pubmed-author:HermannSS,
pubmed-author:HiddemannWW,
pubmed-author:MetznerBB,
pubmed-author:PottCC,
pubmed-author:ReppRR,
pubmed-author:RothmannFF,
pubmed-author:UnterhaltMM,
pubmed-author:WandtHH
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
25
|
|
pubmed:volume |
127
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2253-8
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:12397539-Adult,
pubmed-meshheading:12397539-Aged,
pubmed-meshheading:12397539-Antibodies, Monoclonal,
pubmed-meshheading:12397539-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:12397539-Antimetabolites,
pubmed-meshheading:12397539-Antineoplastic Agents,
pubmed-meshheading:12397539-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12397539-Combined Modality Therapy,
pubmed-meshheading:12397539-Female,
pubmed-meshheading:12397539-Humans,
pubmed-meshheading:12397539-Immunosuppressive Agents,
pubmed-meshheading:12397539-Immunotherapy,
pubmed-meshheading:12397539-Leukemia, Lymphocytic, Chronic, B-Cell,
pubmed-meshheading:12397539-Lymphoma, Follicular,
pubmed-meshheading:12397539-Lymphoma, Mantle-Cell,
pubmed-meshheading:12397539-Lymphoma, Non-Hodgkin,
pubmed-meshheading:12397539-Male,
pubmed-meshheading:12397539-Middle Aged,
pubmed-meshheading:12397539-Mitoxantrone,
pubmed-meshheading:12397539-Recurrence,
pubmed-meshheading:12397539-Remission Induction,
pubmed-meshheading:12397539-Retrospective Studies,
pubmed-meshheading:12397539-Time Factors,
pubmed-meshheading:12397539-Vidarabine
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
[Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
|
|
pubmed:affiliation |
Medizinische Klinik und Poliklinik III, Grosshadern, Klinikum der Universität München, Germany. Roswitha.Forstpointner@med3.med.uni-muenchen.de
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
English Abstract,
Randomized Controlled Trial,
Multicenter Study
|
